dichlororibofuranosylbenzimidazole has been researched along with Osteogenic Sarcoma in 2 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haramoto, N | 1 |
| Kawane, T | 1 |
| Horiuchi, N | 1 |
| Green, E | 1 |
| Todd, B | 1 |
| Heath, D | 1 |
2 other studies available for dichlororibofuranosylbenzimidazole and Osteogenic Sarcoma
| Article | Year |
|---|---|
Upregulation of PTH receptor mRNA expression by dexamethasone in UMR-106 osteoblast-like cells.
Topics: Adenylyl Cyclases; Animals; Cell Line, Tumor; Cyclic AMP; Dexamethasone; Dichlororibofuranosylbenzim | 2007 |
Mechanism of glucocorticoid regulation of alkaline phosphatase gene expression in osteoblast-like cells.
Topics: Alkaline Phosphatase; Animals; Antibodies, Monoclonal; Blotting, Northern; Cell Line; Cycloheximide; | 1990 |